Compier Aggregate Reports

Home / Innovation / Compier Aggregate Reports

Streamline Drug Safety Aggregate Reporting Through Digitalization

Marketing Authorization Holders (MAH) are expected to prepare and submit aggregate safety reports to regional and global regulatory bodies to account for the medicine’s safety profile over an extended period of time. These periodic reports shall be used for assessing the risk-benefit of the product and taking appropriate action where new risks or changes to known risks are identified.

Compier Aggregate Reports

With Compier Aggregate Reports, pharma companies can automate the complete regulatory reporting lifecycle management from pre-approval to post-approval of medicinal products.

It facilitates digital authoring of different types of aggregate reports, online completion of collaborative review and creating a reporting schedule for different regulatory submissions.

Aggregate Reporting

Key Product Features

  • Report Schedule Management: Create and Manage global reporting schedules/timetables with calendar trackers.
  • Predefined Templates – Organizations can leverage predefined Aggregate Report templates for various types of reports such as PADER, PSUR, PBRER, DSUR, CTPR or can define templates as per business requirements
  • Digital Authoring: Author reports within Compier without any dependency on third-party apps
  • Collaborative Review: Schedule, initiate, and complete report content review with multiple teams and reviewers at the same time
  • Workflow driven activities: Define and configure workflows from scheduling, and authoring to submission
  • Regulatory tracking: Acknowledgements received for each submission and amendment can be tracked and reported
  • Access Control: Define controls to who can view, edit, review, approve aggregate reports
  • Version Controlled: Access latest version of aggregate report with archived older versions
  • Correspondence: The module has its own inbox and outbox facility to track information exchange for each record
  • Sharing Aggregate Reports: Allows sharing in various formats such as word, PDF, weblink, etc. through various channels
  • Alerts & Notifications: Stay informed on workflow tasks assignments, workflow tasks, and related activity updates
  • Insights & Analytics: Ready to use and extendable dashboards, data listings and performance indicators

Seamless Integrations with various source systems to enable 100% process automation

  • Drug Safety Database
  • Signal Management System
  • Clinical Systems
  • Quality Management System
  • Literature Screening
  • Other modules of Compier
  • Other organization wide operational data source systems

Aggregate Reporting is a component of our Compier platform. It can be deployed on its own or in combination with other modules of the platform.

Business Analysis

How Do we Deliver

Our technology platform, process accelerators and subject matter expertise enable you with a comprehensive solution to digitalize and automate the entire compliance associated with aggregate reporting. Our solutions are flexible, modular and can be deployed by MAH, QPPV office and CRO companies globally or at local entities.

Request a Product Tour

    Industry Insights

    Best Practices for Signal Management in Pharmacovigilance

    Pharmacovigilance involves the collection, detection, assessment, and monitoring of data on Adverse Drug Reactions (ADRs) which must be evaluated to derive vital safety information. Signal detection involves monitoring the adverse reaction data for patterns that suggest new safety information. Safety signals can be detected from an extensive range of sources, such as spontaneous reports, clinical [...]

    Aggregate Reporting – Significance, Classification and Challenges

    Aggregate reports are the cumulative reports in the database that emphasise on evaluation of safety profile and risk-benefit analysis of a drug. Aggregate reporting is the process of compilation and submission of aggregate reports to the regulatory agencies over the period of the product’s life cycle (during pre-marketing and post-marketing phase) to provide a comprehensive [...]

    Literature Screening – Process overview, challenges en-route and the scope for automation

    Medical and scientific literature is a valuable source of safety information that helps in monitoring benefit-risk profiles and emerging safety issues of medicinal products. Literature screening is conducted to ascertain abstracts and articles that provide crucial information on serious and non-serious Individual Case Safety Reports (ICSR) reports and risk-benefit assessment of a drug. The scientific [...]